Hive Health

These days pharmaceutical companies are faced with shrinking sales forces and reduced access to healthcare professionals. With less time to learn about products and meet with reps, they’re increasingly turning to the internet for information. To help keep up, pharma brands are being pushed to find more effective ways of promoting themselves digitally.

To help solve this problem, Physicians Office Resource (POR), a trusted digital and print resource for over 360,000 US physicians, has launched a new site: PharmaCONNECT. It allows pharmaceutical brands to actively engage the right healthcare professionals, at a convenient time and in a trusted context. The site offers physicians and pharma companies a place to connect in real time or by appointment, in a product agnostic or neutral environment.

By giving digital space (impressions) to pharma brands for free, PharmaCONNECT only charges for successful, active engagements. Active engagements are the types of interactions that can truly impact on prescription decisions, such as a healthcare professional scheduling a rep visit through the POR site, getting eDetailed, clicking to chat with a rep, or a variety of other engagement options.

PharmaCONNECT hopes to create a space where healthcare professionals can have meaningful and measurable engagement that will help pharma companies to get their message across.  The site will also include a resource section and a frequently asked questions page. The site works on the Android and iOS platforms while mobile apps are in development, including a click-to-call feature for iPhone, so healthcare professionals can connect to a rep right away.

Since its launch at the start of this month Novartis, Genentech, Abbott, Bayer Schering, AstraZeneca, BMS, Roche, Pfizer and Boehringer Ingelheim have all already established a multiple brand presence, and POR claims to have 15 to 20 other pharma companies set to join by end of the year.

PharmaCONNECT is currently only operating in the US; it will be interesting to see if it expands globally, and if pharma companies continue to embrace this new platform.